CD274 and non-small cell lung carcinoma: Goldberg’s non-random phase II study showed that when treating BM originating from NSCLC with PD-L1 expression ≥1% with pembrolizumab, the ORR, median OS time, and median PFS time were 29.7% (11/37), 9.9 months (95% CI: 7.5–29.8), and 1.9 months (95% CI: 1.8–3.7), respectively [59].